Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey. more
Time Frame | CTXR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.51% | -3.39% | 0.2% |
1-Month Return | -51.29% | -1.92% | 2.72% |
3-Month Return | -78.2% | -10.54% | 7.31% |
6-Month Return | -82.28% | -4.47% | 10.44% |
1-Year Return | -85.79% | 4.06% | 27.53% |
3-Year Return | -93.04% | 0.94% | 30.88% |
5-Year Return | -81.8% | 36.67% | 89.21% |
10-Year Return | -99.41% | 102.87% | 199.95% |
Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Cost of Revenue | 893.00 | 152.36K | 164.87K | 179.68K | 194.32K | [{"date":"2019-09-30","value":0.46,"profit":true},{"date":"2020-09-30","value":78.41,"profit":true},{"date":"2021-09-30","value":84.85,"profit":true},{"date":"2022-09-30","value":92.47,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Gross Profit | (893.00) | (152.36K) | (164.87K) | (179.68K) | (194.32K) | [{"date":"2019-09-30","value":-89300,"profit":false},{"date":"2020-09-30","value":-15236400,"profit":false},{"date":"2021-09-30","value":-16486800,"profit":false},{"date":"2022-09-30","value":-17967700,"profit":false},{"date":"2023-09-30","value":-19431600,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-09-30","value":null,"profit":false},{"date":"2020-09-30","value":null,"profit":false},{"date":"2021-09-30","value":null,"profit":false},{"date":"2022-09-30","value":null,"profit":false},{"date":"2023-09-30","value":null,"profit":false}] |
Operating Expenses | 15.60M | 17.71M | 23.53M | 33.32M | 36.73M | [{"date":"2019-09-30","value":42.47,"profit":true},{"date":"2020-09-30","value":48.22,"profit":true},{"date":"2021-09-30","value":64.06,"profit":true},{"date":"2022-09-30","value":90.7,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Operating Income | (15.60M) | (17.71M) | (23.53M) | (33.32M) | (36.73M) | [{"date":"2019-09-30","value":-1559836100,"profit":false},{"date":"2020-09-30","value":-1771068500,"profit":false},{"date":"2021-09-30","value":-2353189400,"profit":false},{"date":"2022-09-30","value":-3331604500,"profit":false},{"date":"2023-09-30","value":-3673201800,"profit":false}] |
Total Non-Operating Income/Expense | 72.43K | 214.99K | 728.45K | 502.80K | 5.94M | [{"date":"2019-09-30","value":1.22,"profit":true},{"date":"2020-09-30","value":3.62,"profit":true},{"date":"2021-09-30","value":12.25,"profit":true},{"date":"2022-09-30","value":8.46,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Pre-Tax Income | (15.56M) | (17.55M) | (23.05M) | (33.06M) | (31.97M) | [{"date":"2019-09-30","value":-1556214400,"profit":false},{"date":"2020-09-30","value":-1754808500,"profit":false},{"date":"2021-09-30","value":-2305443400,"profit":false},{"date":"2022-09-30","value":-3306464600,"profit":false},{"date":"2023-09-30","value":-3196691200,"profit":false}] |
Income Taxes | 16.44K | 125.88K | 70.76K | 576.00K | 576.00K | [{"date":"2019-09-30","value":2.85,"profit":true},{"date":"2020-09-30","value":21.85,"profit":true},{"date":"2021-09-30","value":12.28,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Income After Taxes | (15.58M) | (17.67M) | (23.13M) | (33.64M) | (32.54M) | [{"date":"2019-09-30","value":-1557858700,"profit":false},{"date":"2020-09-30","value":-1767396500,"profit":false},{"date":"2021-09-30","value":-2312519000,"profit":false},{"date":"2022-09-30","value":-3364064600,"profit":false},{"date":"2023-09-30","value":-3254291200,"profit":false}] |
Income From Continuous Operations | (15.56M) | (17.55M) | (23.05M) | (33.64M) | (32.54M) | [{"date":"2019-09-30","value":-1556214400,"profit":false},{"date":"2020-09-30","value":-1754808500,"profit":false},{"date":"2021-09-30","value":-2305443400,"profit":false},{"date":"2022-09-30","value":-3364064600,"profit":false},{"date":"2023-09-30","value":-3254291200,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Net Income | (15.58M) | (17.67M) | (23.13M) | (33.64M) | (32.54M) | [{"date":"2019-09-30","value":-1557858700,"profit":false},{"date":"2020-09-30","value":-1767396500,"profit":false},{"date":"2021-09-30","value":-2312519000,"profit":false},{"date":"2022-09-30","value":-3364064600,"profit":false},{"date":"2023-09-30","value":-3254291200,"profit":false}] |
EPS (Diluted) | (0.78) | (0.46) | (0.27) | (0.22) | (0.23) | [{"date":"2019-09-30","value":-78,"profit":false},{"date":"2020-09-30","value":-46,"profit":false},{"date":"2021-09-30","value":-27,"profit":false},{"date":"2022-09-30","value":-22,"profit":false},{"date":"2023-09-30","value":-23,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CTXR | |
---|---|
Cash Ratio | 4.31 |
Current Ratio | 6.75 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CTXR | |
---|---|
ROA (LTM) | -24.74% |
ROE (LTM) | -41.49% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CTXR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CTXR | |
---|---|
Trailing PE | NM |
Forward PE | 9.13 |
P/S (TTM) | 0.00 |
P/B | 0.25 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Citius Pharmaceuticals Inc (CTXR) share price today is $2.66
Yes, Indians can buy shares of Citius Pharmaceuticals Inc (CTXR) on Vested. To buy Citius Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CTXR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Citius Pharmaceuticals Inc (CTXR) via the Vested app. You can start investing in Citius Pharmaceuticals Inc (CTXR) with a minimum investment of $1.
You can invest in shares of Citius Pharmaceuticals Inc (CTXR) via Vested in three simple steps:
The 52-week high price of Citius Pharmaceuticals Inc (CTXR) is $26.75. The 52-week low price of Citius Pharmaceuticals Inc (CTXR) is $2.44.
The price-to-earnings (P/E) ratio of Citius Pharmaceuticals Inc (CTXR) is
The price-to-book (P/B) ratio of Citius Pharmaceuticals Inc (CTXR) is 0.25
The dividend yield of Citius Pharmaceuticals Inc (CTXR) is 0.00%
The market capitalization of Citius Pharmaceuticals Inc (CTXR) is $87.15M
The stock symbol (or ticker) of Citius Pharmaceuticals Inc is CTXR